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Abstract 
Background and purpose: Perfusion imaging is used for patient selection in clinical practice 
and trials. Post-processing and definitions of tissue viability are nevertheless not 
standardised. We compared the lesion volumes generated with two well-recognised perfusion 
tissue definitions in a single centre phase two thrombolysis study.  
Methods: We analysed perfusion imaging data from the Alteplase-Tenecteplase Trial 
Evaluation for Stroke Thrombolysis (ATTEST) study using two popular tissue viability 
thresholds (ischaemic core definition: 1) cerebral blood volume <2.0mL/100g-1 or 2) relative 
cerebral blood flow < 40% that of the contralesional hemisphere and relative delay time >2 
seconds; penumbra definitions: 1) Mean Transit Time >145% of contralesional hemisphere or 
2) relative Delay Time <2 seconds). We compared volumes of core and penumbra, mismatch 
ratio, percentage and volume of penumbra salvaged at 24 hours.  
Results: We included 73 (Tenecteplase= 36, Alteplase=37) patients who had analysable 
perfusion lesions at baseline. Significant differences were found in core volumes using the 
two thresholds (33±37mL versus 26±32mL, p<0.001), as was mismatch ratio (2.5±0.9 versus 
4.2±3.7, p<0.001). The volume of penumbra salvaged at 24 hours (30±19mL versus 
35±26mL, p=0.043) differed significantly, although the percentages of penumbra salvaged 
did not (p=0.2).No difference was found between the two thrombolytic agents in the 
percentages of penumbra salvaged using either threshold.  
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Conclusion: Two commonly used tissue definitions generated significantly different lesion 
volumes, and mismatch ratios. Threshold selection may have significant impact on patient 
selection for trials or reperfusion therapies.   
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Introduction 
Computed tomography perfusion (CTP) imaging has been used widely in both clinical and 
research settings to select candidates for reperfusion therapy, or as a biomarker for efficacy 
and safety. There is no consensus regarding the most accurate thresholds that define 
ischaemic core or penumbral tissue, however, literature-reported viability thresholds were 
derived using a variety of methods, some based on very small numbers of cases,1 and 
implementation on commercial software varies. 
We aimed to compare the lesion volumes generated by two commonly used viability 
thresholds,2,3  and explored potential impact on patient selection.  
Methods 
We used the imaging data from the Alteplase-Tenecteplase Trial Evaluation for Stroke 
Thrombolysis (ATTEST) trial that compared the efficacy and safety of alteplase and 
tenecteplase as thrombolytic agents in acute ischaemic stroke, in which imaging variables 
were the primary outcome but patients were not selected on the basis of imaging criteria. The 
study protocol of ATTEST has been detailed elsewhere.4 Briefly, eligible thrombolysis 
candidates within 4.5h of onset were randomised to receive alteplase (0.9mg/kg to a 
maximum 90mg) or 0.25mg/kg tenecteplase (to a maximum 25mg). Baseline imaging 
comprised non-contrast CT (NCCT), CT perfusion (CTP) and CT angiography (CTA). CTP 
and CTA were undertaken either before or immediately following the thrombolysis bolus to 
avoid treatment delay. Follow-up imaging including NCCT and CTA was carried out 
between 24 and 48 hours post-thrombolysis.  
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All scans were performed on a Philips Brilliance 64 multidetector scanner. Whole brain 
NCCT was acquired first, (5 mm slice thickness FOV 218 x 218 mm, 120 kv, 171 mA or 0·9 
mm slice thickness, FOV 250x250  mm, 120 kV, 404 mA) followed by CTP with 40 mm slab 
coverage from the basal ganglia (8x5 mm slices, FOV 25 cm, 80 kVp, 476 mA, 2 second 
cycle time, 30 cycles) using a 50 ml contrast bolus administered at 5 mls per second (350 
Xenetix) via a large-gauge cannula. A CTA covering aortic arch to the top of the lateral 
ventricles (0·67 mm slice thickness, 120 kV, 475 mA) was acquired during the first arterial 
past of contrast (Xenetix 350, 60 mls, followed by 30 mls of saline bolus, both given at 5 ml 
per second). Follow-up CTA covered from base of skull to the top of lateral ventricles.  
The detailed post-processing and imaging analysis methods were described in the main 
study.4 In summary, CTP was processed offline with MIStar (Apollo Medical Imaging 
Technology, Melbourne, VIC, Australia), which uses a delay-corrected single value 
decomposition (SVD) deconvolution algorithm. 
We used the following definitions: 
 Penumbra volume salvaged = penumbra volume on baseline CTP – penumbra volume 
that infarcted on 24h NCCT;  
 Percentage of penumbra salvaged = (penumbra salvage/penumbra Volume) x 100 
 
We compared two tissue viability thresholds: 
 Wintermark’s definition (MW):2 Irreversible tissue – tissue with reduced Cerebral 
Blood Volume (CBV) <2.0mL/100g; Viable tissue – tissue with relative Mean Transit 
Time (MTT)>145% of contralesional hemisphere and CBV>2.0ml/100g. 
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 Bivard’s definition (AB):3 Irreversible tissue – tissue with reduced CBF (relative CBF 
< 40% that of the contralesional hemisphere) and prolonged Delayed Time (DT) 
(relative DT >2 seconds); Viable tissue – tissue with relative DT>2 seconds and 
rCBF>40%. 
All imaging studies were analysed by two research fellows (XH and BC) twice independently 
with an interval of 4 weeks between processing, and blind to CTA findings. Inter-rater 
agreements were evaluated. For baseline irreversible tissue volume, the intra-class correlation 
coefficient was 0.96 (95% limits of agreement -16-20mL). For penumbra volumes, the 
correlation coefficient was 0.91 with 95% limits of agreement of -30-30mL. The average of 
four readings was taken as the final reading for analysis.  
Values were expressed as mean and standard deviation (SD) or median and interquartile 
range (IQR) depending on normal distribution or not. Paired T tests and related-samples 
Wilcoxon Signed rank tests were used to compare the results produced by the two definitions. 
The differences in the percentage or volume of penumbra salvaged between the two treatment 
groups were compared with independent samples T tests. Statistical analyses were performed 
with IBM SPSS statistics (SPSS Chicago, Illinois, USA v.19) and StatsDirect 2.8. 
Results 
Among the 104 participants in the ATTEST study, 73 (mean age [SD] 73 [11] years; median 
baseline NIHSS [IQR] 13 [9-19]) had measureable perfusion lesions, of whom 36 received 
tenecteplase, and 37 alteplase, at a mean (SD) 189 (46) minutes from symptoms onset. 69 out 
of 73 (93.5%) patients had occlusion on baseline CTA. 
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Table 1 shows the differences between the lesion volumes measured with two thresholds, 
core/penumbra mismatch ratio, the volume and percentage of penumbra salvaged at 24 hours. 
There was a systematic difference in core and penumbra volume estimates with the AB 
method estimating a smaller core and a larger penumbra compared to the MW thresholds 
(Figure 1). The mean differences of the volume and percentage of penumbra salvaged at 24 
hours between the alteplase and tenecteplase treated groups using two thresholds were not 
different.  
The numbers with different “mismatch” ratios did not differ significantly between the two 
thresholds. The effects of applying different patient selection criteria from recent clinical 
trials including core:penumbra ratio, vessel occlusion and core volume are shown in Figure 2. 
Differences in eligibility between the two thresholds ranged from 0% to 43% depending upon 
criteria.  
Discussion 
We observed that different CTP tissue viability thresholds led to significantly different 
estimates of core volume and mismatch ratio. There was no difference in penumbra salvage 
at 24h using the two thresholds, however.  
Despite increasing clinical use, perfusion imaging analysis is not standardised, with 
variability in post-processing algorithms,5,6  and  various combinations of   perfusion 
parameters and thresholds to define core and penumbral tissue.7 The principal purpose of 
defining tissue viability by perfusion imaging is to better estimate the risk:benefit balance for 
reperfusion treatments. Baseline ischaemic core  and penumbra volumes  correlate with 
clinical outcome after intravenous thrombolysis,8,9 and the presence of a “large core” in 
particular signifies higher risk of both intracerebral haemorrhage and significant brain 
8 
 
oedema.10 Observational data suggest that intravenous thrombolysis <4.5h after onset11 or 
late endovascular reperfusion12 are not beneficial in the absence of a “target mismatch” 
pattern, defined as presence of a minimum penumbra volume and ratio of penumbra:core. 
Operational definitions of penumbra and core may thus be important for appropriate 
treatment decisions, but a single definition of what thresholds constitute the most reliable 
estimates of tissue viability may not be possible, as these may depend on the factors noted 
below.  
Comparison of six commonly used post-processing software and different tissue definitions 13 
concluded  that Bivard’s threshold with delay-corrected SVD algorithm was the most 
accurate among several used in currently available post-processing algorithms. Optimal 
thresholds may differ due to factors other than the post-processing algorithm, however, and 
may depend on other factors that have not been investigated systematically including the time 
window for treatment, the specific treatment intervention, and the speed of reperfusion.  
Several multicentre reperfusion studies4,14-20 used perfusion biomarkers to select patients. 
Variability in thresholds applied by both commercial software and in centres may lead to 
variation in patient selection, even with clear imaging selection criteria. Such variation may 
have contributed to the lack of apparent treatment effect in the DIAS-2 trial of 
desmoteplase,18 and reclassification of patients is common when comparing clinician 
interpretation and automated “core lab” processing.11 Recent endovascular reperfusion trials 
that used CTP penumbral selection applied different criteria for “target mismatch” although 
the same post-processing software was employed. The implications of variability in these 
criteria on patient selection are illustrated in Figure 2.   
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Additional acquisition and processing time for multimodal CT assessment may delay  
administration of  thrombolytic treatment, with typical average times for acquisition of 
multimodal imaging 21 of 15 minutes. Whether the potential reduction in benefit resulting 
from this delay is mitigated by improved patient selection and consequently better outcomes 
within the 4.5h time window is under investigation in the ongoing  Penumbra and 
Recanalisation Acute Computed Tomography in Ischaemic Stroke Evaluation (PRACTISE) 
trial.22 
We evaluated only the effect of different perfusion thresholds since other aspects of post-
processing were identical. Multi-centre experience using different equipment and software 
analysis methods will almost certainly be more variable. Several studies have suggested that 
thresholded CBF is more accurate in defining irreversible tissue.23-25 However, some 
commercial software still uses CBV to define infarct core.  In addition to the modest sample 
size, our study has several limitations. The algorithm used in MIStar is a modified SVD with 
compensation for the effects of arterial delay and dispersion,26 whereas the MW thresholds 
were derived with software based on the central volume principle.2 It is possible that MIStar 
is not optimised to process perfusion imaging using the MW definition, as it is not configured 
to allow direct thresholding of core tissue based on cerebral blood volume.13 Our analysis 
was carried out prior to a recent report  that tissue with rDT>3s more closely corresponds to  
penumbra than rDT >2s. 11 , which may affect our  results. Longer acquisition times for CTP 
than were employed in our study may more fully characterise the time:attenuation curve, 
reducing the risk of truncation of the contrast bolus that may occur with low cardiac output 
states, and improving reliability of CBV and CBF estimation. Other technical  limitations 
include using CT to measure final infarct volume, as 24 hours post thrombolysis, the 
infarcted tissue is still poorly defined; and the limited z-axis coverage of CT perfusion  of 
4cm. 
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Conclusion 
Different viability thresholds alone can generate significantly different core volume estimates 
leading to variable mismatch ratio. Clinicians need to consider standardised definitions and 
processing in multicentre studies.  
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Table 1. Differences of lesion size and penumbra salvaged between the measurements of 
the two tissue viability thresholds 
 
 
 AB 
definition3 
MW 
definition2 
Mean/Median 
Difference 
P Value 
(95%CI) 
Ischaemic core 
mL 
Mean (SD) 26 (32) 33 (37) -10 <0.001 
(-13.9− 
 -6.1) 
Median (IQR) 14 (0−41) 25 (0−47) -14 <0.001 
(-20− 
 -7.5) 
Penumbra mL Mean (SD) 51 (30) 45 (25) 5.5 0.058 
(-0.2−11.1) 
Median (IQR) 46 
(29−78) 
42 (25−59) 5 0.091 
(-1−11) 
Volume of 
penumbra 
salvaged mL 
Mean (SD) 35 (26) 30 (19) 4.7 0.043 
(0.2−9.2) 
Median (IQR) 31 
(13−49) 
27 (14−44) 3.5 0.094 
(-0.5−8) 
Percentage of 
penumbra 
salvaged % 
Mean (SD) 68 (25) 70 (25) -2.1 0.2 
(-5.4−1.1) 
Median (IQR) 75 
(50−88) 
78 (51−85) -1.2 0.32 
(-3.7−1) 
Mismatch 
Ratio 
Mean (SD) 4.2 (3.7) 2.5 (0.9) 1.7 <0.001 
(0.9−2.5) 
Median (IQR) 2.9 
(1.9−5) 
2.3 
(1.8−2.9) 
1 <0.001 
(0.6−1.6) 
Recanalisation 
rate§ at 24−48 
hours % 
70% (44/63) [63 out of 73 patients had vessel occlusion on baseline CTA] 
AB=Bivard; MW=Wintermark; SD=Standard Deviation; IQR=Interquartile Range; 
CI=Confidence Interval; CTA= CT Angiography;  p-Value was calculated using paired T-
tests for mean, and related-samples Wilcoxon Signed rank tests for median. § Recanalisation 
was defined as Thrombolysis in Myocardial Infarction (TIMI) 2−3.27,28 
  
Figure 1.  A. Inter-observer Bland-Altman 95% agreement plot for core volume between Bivard (AB) and Wintermark (MW) 
thresholds (mean[green]±1.96SD[black]). Intra-class correlation coefficient= 0.89; 95% limits of agreement (-36.9−22.1); B. Inter-
observer Bland-Altman 95% agreement plot for penumbra volume between AB and MW thresholds. Intra-class correlation coefficient= 
0.78; 95% limits of agreement (-37-45).
  
 Figure 2. We applied four commonly used imaging selection criteria to the 73 patients. This graph shows the percentage of 
patients that is excluded by imaging selection using different criteria. (Selection criteria 1: CT perfusion (CTP) mismatch ratio; 
Selection criteria 2: CTP mismatch ratio and large vessel occlusion [Internal carotid artery, M1(Middle cerebral artery from the 
origin to bifurcation/trifurcation), M2 (from bifurcation to circular sulcus of insula) ]; Selection criteria 3: CTP mismatch ratio, 
large vessel occlusion and core volume <70mL; Selection criteria 4: CTP mismatch ratio, large vessel occlusion, core 
volume<70mL, and penumbra volume >20mL). AB( Bivard) threshold: Irreversible tissue – tissue with reduced Cerebral Blood 
Flow (CBF) (relative CBF < 40% that of the contralesional hemisphere) and prolonged Delayed Time (DT) (relative DT >2 
seconds); Viable tissue – tissue with relative DT>2 seconds and rCBF>40%; MW (Wintermark) threshold: Irreversible tissue – 
tissue with reduced Cerebral Blood Volume (CBV) <2.0mL/100g; Viable tissue – tissue with relative Mean Transit Time 
(MTT)>145% of contralesional hemisphere and CBV>2.0ml/100g. 
 
 
 
